Latanoprost punctal plug - Mati Therapeutics

Drug Profile

Latanoprost punctal plug - Mati Therapeutics

Alternative Names: L-PPDS

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator QLT
  • Developer Mati Therapeutics
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Dec 2016 Mati Therapeutics completes a phase II trial for Ocular hypertension and Glaucoma in USA (NCT02014142)
  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
  • 26 Oct 2016 Mati Therapeutics has patent entitled "Lacrimal Implants and Related Methods" in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top